2016 Anti-Doping Testing Figures Report / World Anti-Doping Agency (WADA). - Montreal : WADA, 2017
Contents:
- Executive Summary - pp. 2-9 (7 pages)
- Laboratory Report -– pp. 10-36 (26 pages)
- Sport Report - pp. 37-150 (113 pages)
- Testing Authority Report - pp. 151-287 (136 pages)
- ABP Report-Blood Analysis - pp. 288-323 (35 pages)
In February 2016 World Rugby has reported an anti-doping rule violation against the Russian rugby player Alena Mikhltsova Bogacheva after her sample, provided on 3 February 2016, tested positive for the prohibited substance Meldonium (Mildronate) in a concentration of 20 ng/mL (0.02 μg/mL). After notification a provisional suspension was ordered. The athlete filed a statement in her defence and she was heard for the World Rugby Judicial Committee.
The Athlete admitted the violation and stated that she had used the substance as prescribed medication. Due to Meldonium would be included in the 2016 Prohibited List she stopped using this medication in October 2015.
On 11 April 2016 the World Anti-Doping Agency (WADA) issued a Notice about Meldonium with guidelines in the circumstances that there may be grounds for no fault or negligence on the part of the Athlete.
The Judicial Committee accepts the Athlete’s explanation and finds that the Athlete established on a balance of probability that the anti-doping violation was neither intentional or reckless. Due to the Athlete ceased taking Meldonium in October 2015, it is seriously questionable whether she could have reasonably apprehended there would be minute quantities of the substance in his system after 1 January 2016 and there was a significant risk it might constitute an anti-doping rule violation.
The Committee determine that there was No Fault or Negligence on the Athlete’s part and that the Athlete’s case came within paragraph number 3 of the WADA Notice (Cases where the concentration is below 1 μg/ml and the test was taken before 1 March 2016). As a result the Judicial Committee concludes that there are grounds to reduce the period of ineligibility from 4 to 2 years and also to eliminate this 2 year period of ineligibility.
Therefore the World Rugby Judicial Committee decides on 3 May 2016, and in its final decision of 3 June 2016, that with the elimination of the 2 year period of inelibilibility the Athlete was permitted to resume playing Rugby immediately.
In February 2016 World Rugby has reported an anti-doping rule violation against the Russian rugby player Aleksey Mikhltsov after his sample, provided on 18 January 2016, tested positive for the prohibited substance Meldonium (Mildronate) in a concentration of 25 ng/mL (0.025 μg/ml). After notification a provisional suspension was ordered. The athlete filed a statement in his defence and he was heard for the World Rugby Judicial Committee.
The Athlete admitted the violation and stated that he acted neither intentional or reckless and that had used the substance as prescribed medication on advice of his club doctor until October 2015. Due to Meldonium would be included in the 2016 Prohibited List he used another medication instead of Meldonium.
On 11 April 2016 the World Anti-Doping Agency (WADA) issued a Notice about Meldonium with guidelines in the circumstances that there may be grounds for no fault or negligence on the part of the Athlete.
The Judicial Committee accepts the Athlete’s explanation and finds that the Athlete established on a balance of probability that the anti-doping violation was neither intentional or reckless. Because the Athlete ceased taking Meldonium in October 2015, it is seriously questionable whether he could have reasonably apprehended there would be minute quantities of the substance in his system after 1 January 2016 and there was a significant risk it might constitute an anti-doping rule violation.
The Committee determines that there was No Fault or Negligence on the Athlete’s part and that the Athlete’s case came within paragraph number 3 of the WADA Notice (Cases where the concentration is below 1 μg/ml and the test was taken before 1 March 2016). As a result the Judicial Committee concludes that there are grounds to reduce the period of ineligibility from 4 to 2 years and also to eliminate this 2 year period of ineligibility.
Therefore the World Rugby Judicial Committee decides on 25 May 2016, and in its final decision of 2 June 2016, that with the elimination of the 2 year period of inelibilibility the Athlete was permitted to resume playing Rugby immediately.
iNADO Update (2017) 86 (6 september)
Institute of National Anti-Doping Organisations (iNADO)
Contents:
- New Member
- Summary of WADA 2016 Testing Figures
- CAS Decision on Therese Johaug reinforces Athlete Strict Liability
- iNADO Members exchange Ideas using iNADO Basecamp Groups
- Recent Study regarding the Prevalence of Doping will be discussed at the iNADO Athlete & Leader Symposium
- Athlete Counselling Service
- New Berlinger Product Line offers Enhanced Security Measures
- ASADA Partnership with CGF for the Gold Coast 2018 Commonwealth Games
- New at the Anti-Doping Knowledge Center
Related case:
CAS 2017_A_5112 Arsan Arashov vs ITF
November 21, 2017
In September 2016 the International Tennis Federation (ITF) has reported an anti-doping rule violation against the minor Kazakh player after his A and B samples tested positive for the prohibited substance Meldonium.
After notification a provisional suspension was ordered. The Athlete filed a statement with objections in his defence and he was heard for the ITF Independent Anti-Doping Tribunal.
The Athlete denied the intentional use of Meldonium and suggested that the sample containers might have been contaminated with Meldonium or the bottles of water from which he drank at the doping control station. He contended that the blood sample he provided the previous day did not show the presence of Meldonium and alleged that departures occurred of the applicable Rules and Standards.
The ITF rejected the Athlete’s contentions and explained that the previous collected blood sample had not been tested for Meldonium. The Athlete had failed to give a plausible explanation for the presence of Meldonium in his sample and no departures occurred from relevant procedures in this case.
The Tribunal was unable to accept the Athlete’s evidence and assertions and concludes that he indeed committed the anti-doping rule violation. Notwithstanding the Athlete’s firm denials, the Tribunal finds that he did in fact ingest Meldonium prior to the sample collection; he failed to assist the Tribunal with helpful and accurate evidence; and failed to establish that the violation was not intentional.
Therefore the ITF Anti-Doping Tribunal decides on 10 April 2017 to impose a proportionate 2 year period of ineligibility on the Athlete starting on the date of the provisional suspension, i.e. on 30 September 2016.
World Anti-Doping Agency 2016 annual report / World Anti-Doping Agency (WADA). - Montreal : WADA, 2017
CONTENTS
- Wada Vision And Mission
- Message From The President And The Director General
- Our Priorities
- Governance
- Executive Committee
- Foundation Board
- Management Team
- Organizational Overview
- The World Anti-Doping Program And The World Anti-Doping Code
- Partnerships
- Code Compliance
- Athlete Relations
- Education
- Intelligence And Investigations
- Science And Medical
- Testing
- Information And Data Management
- Funding
- 2016 Finance Overview
- 2016 Contributions
- 2016 Financial Statements
While WADA’s 2016 priorities included development of new detection methods for doping; conducting new research; equipping Anti-Doping Organizations (ADOs) with tools to protect the integrity of sport; and, monitoring global anti-doping activities; the year was largely consumed by the revelations exposed via the independent Pound and McLaren investigations into Russian sport.
After the Rio Olympic and Paralympic Summer Games, the clean sport community rallied around the need for a more empowered WADA. There was consensus that WADA had accomplished much over its 17 years and that now it was time to equip the Agency with the tools it needs to truly fulfill its mission as the global independent leader of clean sport. Accordingly, at WADA’s 20 November 2016 Foundation Board meeting, the Board approved a series of recommendations for immediate action related to Code compliance; WADA’s Whistleblower Program; WADA’s governance model; the laboratory accreditation system; the Independent Testing Authority (ITA); and, the Anti-Doping Administration and Management System (ADAMS). These recommendations led to the development of a series of priorities that will drive WADA’s work in 2017 and beyond.
At USD28.3 million, WADA’s budget -- which is based on contributions from the public sector that are matched by the International Olympic Committee (IOC) -- has increased slightly over the past five years (2012-2016), growing an average of 1.4% per year. At the same time, WADA’s scope of activities has increased significantly; and, some of those activities, such as investigations, have pulled resourcing from other key activities.
At the end of 2016, WADA employed 88 people from its headquarters in Montreal, Canada; and, its regional offices in Cape Town, South Africa; Tokyo, Japan; Lausanne, Switzerland; and, Montevideo, Uruguay. Together, the WADA team collaborates day-in and day-out with our global partners to preserve the integrity of sport and uphold the values of fair play.
U.S. Anti-Doping Agency 2016 Annual Report / United States Anti-Doping Agency (USADA). - Colorado Springs : USADA, 2017
U.S. Anti-Doping Agency 2015 Annual Report / United States Anti-Doping Agency (USADA). - Colorado Springs : USADA, 2016
